Discovery of Novel <i>N</i>-β-<scp>d</scp>-Xylosylindole Derivatives as Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitors for the Management of Hyperglycemia in Diabetes
activity against sodium-dependentglucosecotransporter2 (SGLT2) in a cell-based assay. Of these, the 4-chloro-3-(4-cyclopropylbenzyl)-1-(β-d-xylopyranosyl)-1H-indole 19m was found to be the most potentinhibitor, with an EC50 value similar to that of the natural SGLT2 inhibitor phlorizin. Further studies in Sprague−Dawley (SD) rats indicated that 19m significantly increased urine glucose excretion in